Published in BMJ on June 06, 1992
Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ (1993) 5.37
Drugs: from prescription only to pharmacy only. BMJ (1993) 1.68
Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines. BMJ (1998) 1.67
United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals. Br J Clin Pharmacol (1993) 1.20
Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol (1998) 1.09
Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm (2010) 0.88
One step forward, one step sideways? Expanding research capacity for neglected diseases. BMC Int Health Hum Rights (2010) 0.85
Postmarketing surveillance of quinolones, 1990 to 1992. Drugs (1993) 0.83
Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol (1998) 0.81
Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacol Toxicol (2014) 0.81
Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed. Br J Clin Pharmacol (1994) 0.77
Social, cultural and ethical aspects of drug use -- changes over 40 years: a personal look back. Eur J Clin Pharmacol (2008) 0.76
Postmarketing surveillance. Avoid promotional studies. BMJ (1994) 0.75
Postmarketing surveillance studies. BMJ (1992) 0.75
Postmarketing surveillance studies. BMJ (1992) 0.75
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Cimetidine: interaction with oral anticoagulants in man. Lancet (1979) 4.67
Monitoring adverse reactions to drugs. Br Med J (1977) 4.41
Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) (1985) 4.30
Uses of barium meal examination in dyspeptic patients under 50. Br Med J (1977) 3.82
A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry (1990) 3.74
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. Gut (1968) 3.46
Adverse drug reactions. BMJ (1998) 3.25
Towards estimation and confidence intervals. Br Med J (Clin Res Ed) (1986) 3.22
Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ (1992) 3.17
20 years of hospital admissions for peptic ulcer in England and Wales. Lancet (1981) 3.06
Changing patterns in epidemiology of Crohn's disease. Lancet (1974) 2.99
Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) (1985) 2.97
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) (1983) 2.90
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
Comprehensive clinical drug information service: first year's experience. Br Med J (1977) 2.77
Effect of different operation policies on mortality from bleeding peptic ulcer. Lancet (1979) 2.74
Aspirin, paracetamol, and haematemesis and melaena. Gut (1982) 2.55
The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55
Epidemiological evidence for the association of aspirin and acute gastrointestinal bleeding. Gut (1970) 2.55
Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet (1979) 2.54
Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol (1987) 2.54
Clinical pharmacology in the National Health Service. J R Soc Med (1978) 2.54
Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J (1973) 2.53
Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol (1992) 2.51
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
The role of the pharmaceutical industry in postgraduate medical education. Br J Clin Pharmacol (1977) 2.45
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) (1982) 2.40
Morphogenesis and fine structure of Frankia (Actinomycetales): the microsymbiont of nitrogen-fixing actinorhizal root nodules. Int Rev Cytol (1987) 2.36
Clinical pharmacology clinics in general practice. Br Med J (1977) 2.28
Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet (1981) 2.25
Smoking and Crohn's disease. Br Med J (Clin Res Ed) (1984) 2.17
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS (1998) 2.16
ABO blood group and secretor status in relation to clinical characteristics of peptic ulcers. Gut (1965) 2.11
Gastric and duodenal ulcer and their associated diseases. Lancet (1976) 2.10
Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J (1980) 2.09
Doctors and the drug makers. Lancet (1984) 2.09
Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med (1985) 2.07
Extending the role of the community pharmacist. BMJ (1991) 2.05
Smoking and ulcerative colitis. Br Med J (Clin Res Ed) (1984) 2.05
Cigarette smoking and inflammatory bowel disease. Gastroenterology (1987) 2.04
Aspirin and bleeding peptic ulcers in the elderly. BMJ (1988) 2.00
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception (1979) 1.97
Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 1.97
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects. Gut (1979) 1.90
Comparison of surgical and medical management of bleeding peptic ulcers. Br Med J (Clin Res Ed) (1982) 1.90
Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J (1980) 1.87
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol (2000) 1.84
Epidemiology of cancer of the large intestine. Proc R Soc Med (1966) 1.83
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol (1984) 1.82
A prospective, randomised study of endoscopy and radiology in acute upper-gastrointestinal-tract bleeding. Lancet (1977) 1.81
Review of yellow cards--1986 and 1987. Br Med J (Clin Res Ed) (1988) 1.81
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
May mothers given warfarin breast-feed their infants? Br Med J (1977) 1.80
[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands]. Ned Tijdschr Geneeskd (1995) 1.79
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) (1985) 1.78
Letter: How do doctors learn about drugs? Lancet (1975) 1.78
Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol (1977) 1.76
Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding. Br J Clin Pharmacol (1975) 1.76
Faecal stasis in proctocolitis. Gut (1962) 1.71
Psoriasis and cancer. Br Med J (1979) 1.71
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol (1989) 1.71
The late results of medical and surgical treatment for bleeding duodenal ulcer. Q J Med (1970) 1.70
What is happening to peptic ulcer? Br Med J (Clin Res Ed) (1982) 1.70
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
Audit of mortality in upper gastrointestinal bleeding. Postgrad Med J (1989) 1.68
New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol (1998) 1.67
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med (1985) 1.65
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS (1997) 1.65
Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet (1983) 1.64
Cimetidine and ranitidine in duodenal ulcer. Br Med J (1980) 1.63
Predicting patients' warfarin requirements. Lancet (1977) 1.61
Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) (1984) 1.57
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
The demographic and social characteristics of patients with Crohn's disease in the Nottingham area. Scand J Gastroenterol (1976) 1.54
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
Coincident salmonella infections and ulcerative colitis: problems of recognition and management. Br Med J (1974) 1.51
Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins. Br J Clin Pharmacol (1975) 1.46
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
Outcome of endoscopy and barium radiography for acute upper gastrointestinal bleeding: controlled trial in 1037 patients. Br Med J (Clin Res Ed) (1982) 1.46
Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) (1987) 1.46
Low prevalence of hepatitis B in mental handicap hospital. Lancet (1989) 1.45
Agent-based computational modeling of wounded epithelial cell monolayers. IEEE Trans Nanobioscience (2004) 1.45
Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol (1981) 1.45
Influence of diet on the "intestinal" component of serum alkaline phosphatase in people of different ABO blood groups and secretor status. Nature (1966) 1.44
Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology (1985) 1.44
Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J (1976) 1.44
Treatment of gastric ulcer with oestrogens. Gut (1968) 1.44
Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol (1991) 1.44
Geographical differences in adverse drug reaction reporting rates in the Northern Region. Br J Clin Pharmacol (1991) 1.43
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol (1991) 1.42
Screening and treatment to prevent post abortion chlamydial pelvic infection. Lancet (1989) 1.42